Hana Algül

18.2k citations
134 papers · 6.7k · 4 hit papers · h-index 39

Impact in

  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • PARP inhibition in cancer therapy
    • Cancer Immunotherapy and Biomarkers
    • Cancer Cells and Metastasis
    • Cancer Genomics and Diagnostics

Papers in

    • Pancreatic and Hepatic Oncology Research 45
    • PARP inhibition in cancer therapy 13
    • Pancreatitis Pathology and Treatment 32

Hana Algül

125 papers receiving 6.6k citations

Hana Algül's Hit Papers

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 2022 · 128 citations
1280+5+10Years since publication50010001.5k

Peers

Hana Algül
Comparison fields: 5 of 128
  • Oncology 3.5k
  • Cancer Research 1.2k
  • Immunology 1.2k
  • Surgery 1.5k
  • Pulmonary and Respiratory Medicine 770
Replace Christoph Michalski with:
Christoph Michalski Germany
Joji Kitayama Japan
Koji Tanaka Japan
Yupei Zhao China
Sylvain Ladoire France
Mark W. Lingen United States
Takatsugu Ishimoto Japan
Byoung‐Gie Kim South Korea
Tetsuo Ohta Japan
Peter Birner Austria
Hana Algül relative to Christoph Michalski Germany Christoph Michalski's profile →
Citations per field
00.5×1.5×2.2×
Christoph Michalski · 1×
Citations per year

Countries citing papers authored by Hana Algül

Since Specialization
Citations

This map shows the geographic impact of Hana Algül's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hana Algül with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hana Algül more than expected).

Fields of papers citing papers by Hana Algül

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hana Algül. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hana Algül. The network helps show where Hana Algül may publish in the future.

Co-authors

The 25 scholars most cited alongside Hana Algül, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hana Algül Line = papers co-authored together Hana Algül links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 134 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Hit paper breakdown →
20191530
2
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Hit paper breakdown →
2011682
3
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Hit paper breakdown →
2015427
4 2017267
5 2013217
6 2013150
7 2014146
8 2007145
9 2018137
10
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Hit paper breakdown →
2022128
11 2016124
12 2014115
13 201298
14 201698
15 200286
16 201483
17 200783
18 200778
19 201673
20 201371

About Hana Algül

Hana Algül is a scholar working on Oncology, Surgery, Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 134 papers that have together received 6.7k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (45 papers), Pancreatitis Pathology and Treatment (32 papers), Cancer Genomics and Diagnostics (15 papers), PARP inhibition in cancer therapy (13 papers), Gallbladder and Bile Duct Disorders (13 papers), NF-κB Signaling Pathways (9 papers), Economic and Financial Impacts of Cancer (7 papers) and Phagocytosis and Immune Regulation (7 papers). The work is most often cited by research in Oncology (3.5k citations), Cancer Research (1.2k citations), Immunology (1.2k citations), Surgery (1.5k citations) and Pulmonary and Respiratory Medicine (770 citations). Hana Algül has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Marina Lesina, Roland M. Schmid, Matthias Treiber, Thomas M. Gress, Sonja M. Wörmann, David A. Tuveson, Albrecht Neeße, Michele Reni, Anke Reinacher‐Schick and Daniel Hochhauser. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Gastroenterology, PLoS ONE and Pancreatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact